BNR on Nasdaq
Burning Rock Biotech Ltd
Burning Rock Biotech Ltd is a medical laboratories services company, listed on Nasdaq (BNR).1
$15.71 up 1.10 (7.53%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 20, 2026.
Overview
Compare with Personalis (United States), BIODESIX INC or Exagen Inc., or pick any stock.
- TickerBNR on Nasdaq1
- IndustryServices-Medical Laboratories1
- Business addressNo. 5 Xingdao Ring Road North,, International Bio Island, Guangzhou, Guangdong, 5100054
- Filer categoryNon-accelerated filer4
See how the biggest companies compare on our leaderboards
We conduct our NGS-based products and services business primarily through the wholly-owned subsidiaries of the VIE, Guangzhou Burning Rock Dx Co., Ltd. and Guangzhou Burning Rock Medical Equipment Co., Ltd., which were established in March 2014 and January 2015, respectively.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue25¢$19.5M
- Research and development31¢$23.8M
- Other costs44¢$33.6M
- Income tax0¢$223.0K
Out of $77.2M in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $65.9M6 | $79.7M7 | $81.7M8 | $75.7M9 | $70.7M10 | $77.2M3 | |
| Cost of revenue | $17.8M6 | $22.6M7 | $26.6M8 | $24.5M9 | $21.0M10 | $19.5M3 | |
| Gross profit | $48.1M6 | $57.1M7 | $55.1M8 | $51.2M9 | $49.6M10 | $57.6M3 | |
| Research and development | $40.5M6 | $57.7M7 | $61.2M8 | $48.9M9 | $31.8M10 | $23.8M3 | |
| Operating income | -$63.2M6 | -$125.1M7 | -$142.1M8 | -$94.3M9 | -$49.0M10 | -$7.8M3 | |
| Interest | $102.0K6 | $241.0K7 | |||||
| Income before tax | -$124.9M7 | -$140.5M8 | -$91.7M9 | -$46.7M10 | -$7.7M3 | ||
| Income tax | $06 | $141.0K7 | $288.0K8 | $336.0K9 | $806.0K10 | $223.0K3 | |
| Net income | -$62.4M6 | -$125.0M7 | -$140.8M8 | -$92.1M9 | -$47.5M10 | -$7.9M3 |
No quarterly figures reported.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash | $15.1M6 | $290.5M6 | $224.6M7 | $131.3M8 | $86.6M9 | $71.2M10 | $68.4M3 |
| Receivables | $14.5M7 | $15.9M8 | $17.9M9 | $20.8M10 | $24.3M3 | ||
| Inventory | $19.3M7 | $18.9M8 | $9.7M9 | $8.6M10 | $6.9M3 | ||
| Current assets | $386.8M6 | $285.7M7 | $182.5M8 | $124.5M9 | $106.4M10 | $105.6M3 | |
| Property, plant and equipment | $51.1M7 | $36.5M8 | $18.6M9 | $6.5M10 | $4.4M3 | ||
| Intangible assets | $808.0K7 | $288.0K8 | $136.0K9 | $58.0K10 | $41.0K3 | ||
| Total assets | $408.1M6 | $357.6M7 | $230.2M8 | $146.5M9 | $121.3M10 | $117.3M3 | |
| Accounts payable | $9.9M7 | $7.4M8 | $2.5M9 | $4.6M10 | $5.8M3 | ||
| Short-term debt | 0 CNY7 | $08 | |||||
| Current liabilities | $37.0M6 | $58.4M7 | $59.7M8 | $37.1M9 | $36.5M10 | $35.3M3 | |
| Long-term liabilities | $9.6M7 | $2.6M8 | $1.2M9 | $5.2M10 | $5.5M3 | ||
| Total liabilities | $37.1M6 | $68.0M7 | $62.2M8 | $38.3M9 | $41.7M10 | $40.8M3 | |
| Retained earnings | -$349.7M7 | -$463.9M8 | -$542.8M9 | -$575.4M10 | -$608.5M3 | ||
| Shareholders’ equity | $371.0M6 | $289.6M7 | $167.9M8 | $108.2M9 | $79.6M10 | $76.5M3 | |
| Shares outstanding | 25.0M shares6 | 0 shares6 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$11.3M6 | -$75.0M7 | -$66.2M8 | -$36.0M9 | -$12.6M10 | -$4.1M3 | |
| Depreciation and amortization | $7.5M7 | $18.0M8 | $18.8M9 | $7.2M10 | $3.1M3 | ||
| Stock-based compensation | $44.3M7 | $47.4M8 | $36.7M9 | $21.3M10 | $2.0M3 | ||
| Capital spending | $9.2M6 | $32.1M7 | $9.0M8 | $1.1M9 | $742.0K10 | $751.0K3 | |
| Free cash flow | -$20.5M | -$107.1M | -$75.2M | -$37.2M | -$13.4M | -$4.8M | |
| Cash from investing | $12.8M7 | -$1.1M8 | -$1.3M9 | -$604.0K10 | -$628.0K3 | ||
| Share buybacks | $06 | $07 | |||||
| Cash from financing | -$8.3M7 | -$12.5M8 | -$6.9M9 | -$10.0K10 | $272.0K3 |
Corporate structure
Burning Rock Biotech Ltd sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Burning Rock Biotech Ltd
- Kynam Capital Management, LP Filed SCHEDULE 13G/A on Burning Rock Biotech Ltd, latest May 15, 2026 (6 filings since Feb 10, 2023)
- CRCM LP Filed SCHEDULE 13G/A on Burning Rock Biotech Ltd, latest May 13, 2026 (2 filings since Dec 19, 2025)
- HSG Holding Ltd Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 14, 2024
- LAV Biosciences Fund V, L.P. Filed SC 13G on Burning Rock Biotech Ltd, latest Feb 13, 2024
- GIC Private Limited Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 9, 2024 (2 filings since Feb 10, 2022)
- CMB International Capital Corp Ltd Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 13, 2023 (2 filings since Feb 7, 2022)
- Northern Light Venture Fund III, L.P. Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 13, 2023
- Yusheng Han Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 2, 2023
- BAILLIE GIFFORD & CO Filed SC 13G/A on Burning Rock Biotech Ltd, latest Jul 5, 2022 (2 filings since Jan 12, 2022)
- HSG Venture VI Holdco, Ltd. Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 11, 2022
- Right Lane Ltd Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 11, 2022
- LYFE CAPITAL MANAGEMENT LTD Filed SC 13G/A on Burning Rock Biotech Ltd, latest Feb 7, 2022
- Burning Rock Biotech Ltd
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Burning Rock Biotech Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $74.6M3 Dec 31, 2025 | $72.4M10 Dec 31, 2024 | +3.0% |
| Accumulated depreciation | $65.5M3 Dec 31, 2025 | $61.4M10 Dec 31, 2024 | +6.7% |
| Property and equipment, net | $4.4M3 Dec 31, 2025 | $6.5M10 Dec 31, 2024 | −31.2% |
| Operating-lease assets (leased space) | $6.1M3 Dec 31, 2025 | $7.3M10 Dec 31, 2024 | −16.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $68.4M3 Dec 31, 2025 | $71.2M10 Dec 31, 2024 | −3.9% |
| Stakes in other companies (equity method) | $010 Dec 31, 2024 | $47.0K9 Dec 31, 2023 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $41.0K3 Dec 31, 2025 | $58.0K10 Dec 31, 2024 | −29.3% |
| Finite-lived intangibles, gross | $1.8M3 Dec 31, 2025 | $1.7M10 Dec 31, 2024 | +4.3% |
| Accumulated amortization | $1.7M3 Dec 31, 2025 | -$1.6M10 Dec 31, 2024 | +205.5% |
Inventory
Leadership
Who has led Burning Rock Biotech Ltd, and when. Pick a name to see everywhere that person has worked.
Board members and other officers (4)
- Board memberLicen Lisa Xu Mar 17, 2026 to now11
- Board memberYusheng Han Mar 17, 2026 to now12
- Board memberZhihong Zhang Mar 17, 2026 to now13
- Board memberFeng Deng Mar 18, 2026 to now14
Calendar
Coming up
- Nov 19, 2026Reports results for the quarter ending Sep/202615
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
116 filings to the SEC since October 2021: 6 annual reports, 8 insider forms, 21 large holders, 81 other. The latest 20:
- Sep 10, 20266-K EDGAR
- Jul 2, 20264 EDGAR
- Jun 9, 20266-K EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 13, 2026SCHEDULE 13G/A EDGAR
- Apr 28, 202620-F EDGAR
- Apr 2, 20264 EDGAR
- Mar 18, 20263 EDGAR
- Mar 17, 20263 EDGAR
- Mar 17, 20263 EDGAR
- Mar 17, 20263 EDGAR
- Mar 17, 20263 EDGAR
- Mar 17, 20263 EDGAR
- Mar 13, 20266-K EDGAR
- Dec 23, 20256-K EDGAR
- Dec 19, 2025SCHEDULE 13G EDGAR
- Dec 1, 20256-K EDGAR
- Nov 20, 20256-K EDGAR
- Nov 14, 2025SCHEDULE 13G/A EDGAR
- Sep 8, 20256-K EDGAR
The 116 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Han YushengDirector | Buy | 24,900 | $8.00 | $199.2K | Form 4 |
| Jun 24, 2026 | Han YushengDirector | Buy | 250,000 | $8.00 | $2.0M | Form 4 |
| Jun 23, 2026 | Han YushengDirector | Buy | 5,990 | $7.50 | $44.9K | Form 4 |
| Jun 22, 2026 | Han YushengDirector | Buy | 104,650 | $7.45 | $779.6K | Form 4 |
| Jun 16, 2026 | Han YushengDirector | Buy | 111,110 | $9.00 | $1.0M | Form 4 |
| Jun 12, 2026 | Han YushengDirector | Buy | 210,000 | $9.25 | $1.9M | Form 4 |
| Jun 11, 2026 | Han YushengDirector | Buy | 24,760 | $8.74 | $216.4K | Form 4 |
| Mar 31, 2026 | Han YushengDirector | Buy | 314,870 | $17.36 | $5.5M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Kynam Capital Management, LPSCHEDULE 13G/A, 6 filings Feb 10, 2023 to May 15, 202616
- CRCM LPSCHEDULE 13G/A, 2 filings Dec 19, 2025 to May 13, 202617
- HSG Holding LtdSC 13G/A, 1 filing Feb 14, 202418
- LAV Biosciences Fund V, L.P.SC 13G, 1 filing Feb 13, 202419
- GIC Private LimitedSC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202420
- CMB International Capital Corp LtdSC 13G/A, 2 filings Feb 7, 2022 to Feb 13, 202321
- Northern Light Venture Fund III, L.P.SC 13G/A, 1 filing Feb 13, 202322
- Yusheng HanSC 13G/A, 1 filing Feb 2, 202323
- BAILLIE GIFFORD & COSC 13G/A, 2 filings Jan 12, 2022 to Jul 5, 202224
- HSG Venture VI Holdco, Ltd.SC 13G/A, 1 filing Feb 11, 202225
- Right Lane LtdSC 13G/A, 1 filing Feb 11, 202226
- LYFE CAPITAL MANAGEMENT LTDSC 13G/A, 1 filing Feb 7, 202227
SEC filer profile
How Burning Rock Biotech Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBurning Rock Biotech Ltd1
- CIK0001792267
- Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
- Incorporated inCayman Islands5
- Industry code (SIC)8071 Services-Medical Laboratories1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressNo. 5 Xingdao Ring Road North,, International Bio Island, Guangzhou, Guangdong, 510005, China1
- Phone86 185016416661
- Shares outstanding87,857,741 Common Class A shares; 651,908 Adr shares; 3,023,138 Treasury Stock Common shares; 17,324,848 Common Class B shares as of Dec 31, 20255
- AuditorErnst & Young Hua Ming LLP, Shanghai, the People’s Republic of China PCAOB ID 1408; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceNov 4, 20191
- Filings169 in all: 6-K (57), CORRESP (17), UPLOAD (15), SC 13G/A (14), SC 13G (11), 20-F (6), 3 (6), F-3/A (5)1
All 29 form types
DRSLTR (4), EFFECT (4), DRS/A (3), F-1/A (3), SCHEDULE 13G/A (3), 4 (2), 424B4 (2), DRS (2), F-1 (2), F-6 POS (2), 20-F/A (1), 424B3 (1), 424B5 (1), 8-A12B (1), CERT (1), F-1MEF (1), F-3 (1), F-6 (1), FWP (1), S-8 (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (20-F) Apr 28, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| American depositary shares, each representing ten Class A ordinary shares, par value US$0.0002 per share | BNR | The Nasdaq Stock Market LLC |
| Class A ordinary shares, par value US$0.0002 per share | The Nasdaq Stock Market LLC |
From the cover page of the 20-F filed Apr 28, 2026 (Section 12(b) of the Exchange Act).5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceBNR quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARLicen Lisa Xu, Board member
- 12SEC EDGARYusheng Han, Board member
- 13SEC EDGARZhihong Zhang, Board member
- 14SEC EDGARFeng Deng, Board member
- 15NasdaqNasdaq calendar
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27